Hybar Raises $1.1B in Funding

Gynger

Gynger is an AR management and embedded financing solution that gives B2B technology vendors the power to offer flexible payment terms to customers while securing up front payment. With Gynger, finance leaders can leverage a combination of actionable insights and capital to optimize day-to-day cash flows, accelerate deal flows, and execute long term strategic vision with ease. Learn more about how Gynger helps tech vendors take control of receivables at www.gynger.io

AltExchange

AltExchange is now part of iCapital.

Clicklease

Clicklease is the payment solution that says “yes.” Our innovative payment solution connects equipment vendors with small businesses through flexible, affordable payment plans. The solution’s proprietary algorithm doesn’t need to consider FICO scores for approval, empowering customers who can’t get funding otherwise. Business owners simply shop for the equipment they need on their favorite vendor websites, click to apply for Clicklease payments, complete the 4-minute application, receive instant approval, and enjoy same-day funding. Our solution is a win-win. It not only helps small businesses buy what they need to succeed, it helps equipment vendors sell what they need to grow. And when businesses grow, so do families, communities, and economies.

Parabilis Medicines

Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact.

Able Made

Sustainable athleisure for the active and the activists, powering a global movement that unites us for the love of the game, the planet and each other.